LIGAND PHARMACEUTICALS INC
LGND · XNASCIK 886163fmd_0XVYEMTZV7VE3Z95T60KZGPNHKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2007 to Sep 30, 2026, 68 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 109 | 141 | 251 | 120 | 164 | 242 | 196 | 131 | 167 | 268 |
| Net interest income | (12) | (11) | – | – | – | – | – | – | – | – |
| Cost of revenue | 6 | 5 | 6 | – | – | – | – | – | – | – |
| Gross profit | 103 | 136 | 245 | – | – | – | – | – | – | – |
| Realized investment gains (losses) | 2 | 1 | 3 | 0 | (17) | (5) | 29 | 46 | 75 | 18 |
| Research and development | 21 | 27 | 28 | 56 | 41 | 32 | 36 | 25 | 21 | 81 |
| Operating income | 44 | 68 | 164 | 807 | 38 | 104 | 3 | 12 | (23) | 41 |
| Interest expense | 13 | 13 | 48 | 36 | 27 | 20 | 2 | 1 | 3 | 5 |
| Interest and investment income | – | 2 | 14 | 28 | 8 | 1 | 2 | 8 | 8 | 14 |
| Other non-operating income (expense) | (36) | (11) | 10 | (10) | (36) | (32) | 33 | 52 | 25 | 118 |
| Income before taxes | 8 | 57 | 173 | 797 | 1 | 72 | 36 | 64 | 3 | 159 |
| Income tax expense | 10 | 45 | 30 | 167 | (5) | (4) | 41 | 10 | 7 | 35 |
| Net income from continuing operations | (2) | 13 | 143 | 629 | 7 | 76 | (5) | 54 | (4) | 124 |
| Net income | (2) | 13 | 143 | 629 | (3) | 57 | (33) | 52 | (4) | 124 |